Coverage Policy Manual
Policy #: 2024008
Category: Pharmacy
Initiated: March 2024
Last Review: February 2026
Travoprost Intracameral implant (iDose TR)

Description:
Travoprost intracameral implant (e.g., iDoseTR) is a prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT). Travoprost  is a long duration, intracameral procedural pharmaceutical therapy designed to deliver around-the-clock therapeutic levels of a proprietary formulation of travoprost inside the eye for extended periods.
 
It is made from medical-grade titanium and is implanted through the trabecular meshwork and back wall of Schlemm's canal, directly into scleral tissue. Once implanted, 75 mcg of a novel, preservative-free, proprietary formulation of travoprost continuously elutes into the anterior chamber via membrane-controlled diffusion, allowing for the 24/7 release of medication. travoprost intracameral implant is designed such that it can be removed and replaced with a new travoprost intracameral implant, thus potentially offering a long-term alternative to daily eye drop treatment. Travoprost intracameral implant is intended to address ubiquitous patient non-compliance and chronic side effects associated with topical IOP-lowering medications.
 
Regulatory Status
 
The U.S. Food and Drug Administration, (FDA) approved travoprost intracameral implant (e.g., iDose TR) New Drug Application on December 14, 2023 for a single administration per eye, indicated for the reduction of IOP in individuals with OAG or OHT.
 
Coding
 
See CPT/HCPCS Code section below

Policy/
Coverage:
Effective November 01, 2026
 
Does Not Meet Primary Coverage Criteria Or Is Not Covered For Contracts Without Primary Coverage Criteria
 
Travoprost intracameral implant (iDose TR) does not meet member benefit certificate Primary Coverage Criteria that there be scientific evidence of effectiveness in improving health outcomes and are not covered for any indication or circumstance not described above.
 
For contracts without Primary Coverage Criteria, Travoprost intracameral implant (iDose TR), is considered not Medically Necessary and is not covered or are investigational for any indication or circumstance not described above. Not Medically Necessary or Investigational services are specific contract exclusions in most member benefit certificates of coverage.
 
Click the following link to view the specific criteria in InterQual®: https://prod.ds.interqual.com/service/connect/transparency?tid=27b0a724-ca06-4b22-846b-598b8dae52fc
 
Effective February 2026 to October 31, 2026
 
Does Not Meet Primary Coverage Criteria Or Is Investigational For Contracts Without Primary Coverage Criteria
 
Travoprost intracameral implant (iDose TR), for any indication or circumstance, does not meet member benefit certificate Primary Coverage Criteria that there be scientific evidence of effectiveness in improving health outcomes and is not covered.
 
For members with contracts without Primary Coverage Criteria, Travoprost intracameral implant (iDose TR) for any indication, condition or circumstance not described above is considered not Medically Necessary and is not covered or is investigational. Investigational services are specific contract exclusions in most member benefit certificate of coverage.
 
Effective March 2024 to January 2026
 
Does Not Meet Primary Coverage Criteria Or Is Investigational For Contracts Without Primary Coverage Criteria
 
The use of travoprost intracameral implant, for any indication or circumstance, does not meet member benefit certificate primary coverage criteria that there be scientific evidence of effectiveness above, including:
 
For members with contracts without primary coverage criteria, the use of travoprost intracameral implant for the treatment of any indication, condition or circumstance not described above is considered investigational.
Investigational services are specific contract exclusions in most member benefit certificate of coverage.
 

Rationale:
In a randomized, double-masked, multicenter, phase 2 trial to evaluate the long-term safety and efficacy of travoprost intraocular implant, patients with OAG or OHT were administered a fast-eluting implant (FE implant, n=51) or a slow-eluting implant (SE implant n=54) [Berdahl JP, et. al., 2023]. Both groups received twice a day (BID) placebo eye drops or underwent a sham surgical procedure and received BID timolol 0.5% (n=49). Efficacy was evaluated by mean change from 8:00 AM unmedicated baseline IOP through month 36, and the same or fewer IOP lowering medications as at pre-study screening. Safety was evaluated by adverse events and ophthalmic parameters.
 
Clinically and statistically relevant IOP-lowering treatment effects were observed through month 36 after a single administration of travoprost implant compared with BID timolol with mean IOP reductions ranging from 7.6 – 8.8 mmHg for the FE implant group, from 7.3 – 8.0 mmHg for the SE implant group and from 7.3-7.9 for the timolol group at the 8:00 AM timepoint (P<0.0001 for all treatment groups at all visits).  At months 12, 24, and 36, a greater percentage of FE and SE implant patients versus timolol patients were well controlled on the same or fewer topical IOP-lowering medications compared with screening with 63 and 69% for the FE and SE implant groups respectively, versus 45% for the timolol group at month 36.
 
The FDA approval is based on results from two prospective, randomized, multicenter, double-masked, Phase 3 pivotal trials (GC-010 and GC-012) designed to compare the safety and efficacy of a single administration of one of two travoprost intraocular implant models with different travoprost release rates (referred to as the fast- and slow-release  models, respectively) to topical timolol ophthalmic solution, 0.5% BID (twice a day), in reducing IOP in subjects with open-angle glaucoma or ocular hypertension. In total, the Phase 3 trials randomized 1,150 subjects across 89 clinical sites.
 
Both Phase 3 trials successfully achieved the pre-specified primary efficacy endpoints through 3 months and demonstrated a favorable tolerability and safety profile through 12 months. IOP reductions from baseline over the first 3 months were 6.6-8.4 mmHg in the travoprost intraocular implant arm, versus 6.5-7.7 mmHg in the timolol control arm (mmHg range represents IOP reduction means across the six U.S. FDA pre-specified timepoints of 8 a.m. and 10 a.m. at Day 10, Week 6 and Month 3). Based on these outcomes, the FDA concluded in the prescribing information that travoprost intraocular implant demonstrated non-inferiority to timolol ophthalmic solution in IOP reduction during the first 3 months. The FDA also noted that subsequently travoprost intraocular implant did not demonstrate non-inferiority over the next 9 months.
 
At 12 months, 81% of  travoprost intraocular implant subjects were completely free of IOP-lowering topical medications across both trials. In both trials, travoprost intraocular implant demonstrated excellent tolerability and subject retention with 98% of travoprost intraocular implant subjects continuing in the trial at 12 months, versus 95% of timolol control subjects. In controlled studies, the most common ocular adverse reactions reported in 2% to 6% of travoprost intraocular implant patients were increases in intraocular pressure, iritis, dry eye, and visual field defects, most of which were mild and transient in nature.
 
2025 Update
Annual policy review completed with a literature search using the MEDLINE database through March 2025. No new literature was identified that would prompt a change in the coverage statement.
 
2026 Update
Annual policy review completed with a literature search using the MEDLINE database through February 2026. No new literature was identified that would prompt a change in the coverage statement.

CPT/HCPCS:
C9399Unclassified drugs or biologicals
J3490Unclassified drugs
J7355Injection, travoprost, intracameral implant, 1 microgram

References:
American Academy of Ophthalmology Preferred Practice Pattern Glaucoma Panel, Hospkins.(2020) Center for Quality Eye Care(2020) Primary Open-Angle Glaucoma 2020. https://www.aao.org/preferred-practice-pattern/primary-open-angle-glaucoma-ppp.

Belamkar A, Harris A, Zukerman R, et al.(2022) Sustained release glaucoma therapies: Novel modalities for overcoming key treatment barriers associated with topical medications. Ann Med. 2022;54(1):343-358. doi:10.1080/07853890.2021.1955146

Berdahl JP, Sarkisian SR Jr, Ang RE, et al.(2024) Efficacy and Safety of the Travoprost Intraocular Implant in Reducing Topical IOP-Lowering Medication Burden in Patients with Open-Angle Glaucoma or Ocular Hypertension. Drugs. 2024;84(1):83-97. doi:10.1007/s40265-023-01973-7

iDose® TR [package insert]. San Clemente, CA: Glaukos Corp, 2023

Parul Ichhpujani, Thakur S.(2023) iDose TR Sustained-release Travoprost Implant for the Treatment of Glaucoma. touchREVIEWS in Ophthalmology. 2023;17(1):4-4. doi:https://doi.org/10.17925/usor.2023.17.1.4

Sarkisian, S.R., Ang, R.E., Lee, A.M. et al.(2024) Travoprost Intracameral Implant for Open-Angle Glaucoma or Ocular Hypertension: 12-Month Results of a Randomized, Double-Masked Trial. Ophthalmol Ther (2024). https://doi.org/10.1007/s40123-024-00898-y


Group specific policy will supersede this policy when applicable. This policy does not apply to the Wal-Mart Associates Group Health Plan participants.
CPT Codes Copyright © 2026 American Medical Association.